enGene Therapeutics Inc. — Form 10-Q
Filed September 8, 2026 · analyzed by the Periodic Agent
10-Q
▼ Likely negative
significance 62/100
What the filing says
enGene terminated ~35 employees on July 15, 2026 (reduction in force), paying severance of $517.9K (Daws), $473.8K (Giguere), $513.8K (Nichols), and $484.4K (Cheung, 18-month term as consultant). Simultaneously hired Kathleen Richton as SVP Finance at $370K base + 35% bonus, effective July 16, 2026. Also hired interim CMO William Grossman part-time at $25K/month with 200K options. Key execs departing include CFO, Chief Legal Officer, and VP IT.
Why this rating
RIF costs ~$2M severance (>1% of $154M market cap) + executive churn signals distress. Offset by manageable new hires, but leadership instability and near-term burn are material.
See more from September 8, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.